Guillerme S, Delarue J, Thereaux J
Department of Nutrition, CHRU/Faculty of Medicine/University of Brest, France.
Department of Nutrition, CHRU/Faculty of Medicine/University of Brest, France; ER 7479 SPURBO, Faculty of Medicine/University of Brest, France.
J Visc Surg. 2023 Apr;160(2S):S15-S21. doi: 10.1016/j.jviscsurg.2022.12.009. Epub 2023 Jan 30.
Bariatric surgery (BS) leads to substantial weight loss accompanied by reversal of several obesity-related co-morbidities and reduced mortality. However, surgery is associated with risks and its nearly irreversible characteristic requires a clearly established pre- and postoperative clinical pathway. In France, this pathway relies on recommendations made by the High Authority of Health (Haute Autorité de santé (HAS)) in 2009; an update is awaited in 2023.
BS should be proposed only after failure of well-conducted medical treatment and is intended for patients whose body mass index (BMI) is ≥40kg/m or for those with BMI ≥35kg/m who also have co-morbidities amenable to improvement, and in whom there are no contra-indications, particularly, those related to general anesthesia or psychological factors. The success and safety of surgical management requires preparation of the patient with regard to dietetic and nutritional counseling, and physical activity. The possibility of complications must be recognized and communicated, including, in view of the large variability of outcomes between individuals, the risk of failure and regain of weight.
Prior to the operation, patients should be informed of and accept the program of postoperative clinical and laboratory follow-up, as well as the need for lifelong supplementation in micronutrients and the financial implications including what patients may have to pay out of their own pocket.
Surgical management of obesity cannot replace the multidisciplinary medical management of severe obesity. The results obtained by BS are sustainable only if the patient adheres to the proposed modalities. New drugs such a GLP-1 analogues have opened encouraging perspectives as possible alternatives to BS in certain indications.
减肥手术可导致显著体重减轻,同时逆转多种与肥胖相关的合并症并降低死亡率。然而,手术存在风险,其几乎不可逆转的特性需要明确建立术前和术后临床路径。在法国,该路径依赖于2009年法国卫生高级管理局(Haute Autorité de santé (HAS))提出的建议;预计2023年会有更新。
只有在规范的药物治疗失败后才应考虑进行减肥手术,手术对象为身体质量指数(BMI)≥40kg/m²的患者,或BMI≥35kg/m²且伴有可改善的合并症、无禁忌证(特别是与全身麻醉或心理因素相关的禁忌证)的患者。手术管理的成功与安全需要对患者进行饮食和营养咨询以及体育活动方面的准备。必须认识并告知可能出现的并发症,鉴于个体间结果差异很大,还包括手术失败和体重反弹的风险。
手术前,应告知患者并使其接受术后临床和实验室随访计划,以及终身补充微量营养素的必要性和经济影响,包括患者可能需要自掏腰包支付的费用。
肥胖的手术管理无法替代严重肥胖的多学科医疗管理。只有患者坚持所建议的方式,减肥手术取得的效果才可持续。新型药物如GLP-1类似物在某些适应症中作为减肥手术的可能替代方案开辟了令人鼓舞的前景。